Modafinil, a prescription medication that promotes wakefulness, treats disorders of excessive daytime sleepiness and is also used for clearer focus. It reliably improves alertness in sleep disorders and during sleep loss; in rested, healthy adults the gain in thinking is real but small. Headache, nausea, anxiety and lost sleep are common, and lost sleep matters most for longevity strategies resting on sleep. No study links it to longer life. (Full Review)

Protocol

Label regimen for sleep disorders

200 mg once each morning

Or about one hour before a night shift; 400 mg adds no consistent benefit

Cognitive-use doses in trials

Single 100 or 200 mg dose

Both doses performed alike in rested adults

Best time of day

Morning, on waking

Food delays the peak by about one hour without reducing absorption

Time to effect

Alertness

Within hours

Blood levels peak 2–4 hours after a dose; no build-up period is needed

Cognitive performance

Single dose

Trials measured gains after one dose; clearest on complex tasks

Benefits

High: Sustained wakefulness in sleep disorders and during sleep loss; small gains in cognitive performance in rested adults

Medium: Less fatigue in chronic neurological and medical illness

Low: Add-on improvement in depression; adult attention-deficit symptoms; negative symptoms of schizophrenia; reduced stimulant use

Speculative: Protection of dopamine-producing neurons; anti-inflammatory effects

Contraindications

Known hypersensitivity to modafinil or armodafinil (contraindicated)

Prior serious rash, angioedema or multi-organ hypersensitivity with modafinil or armodafinil

Left ventricular hypertrophy, or mitral valve prolapse with prior stimulant-related chest pain, ischemic ECG changes or arrhythmia

Uncontrolled high blood pressure or irregular heartbeat

Pregnancy or planned pregnancy

Children and adolescents under 17 years

Active psychosis or mania

Key Interactions

Hormonal contraceptives (oral ethinyl estradiol, patches, rings): risk of contraceptive failure (during use and for one month after stopping)

CYP3A4 substrates (triazolam, cyclosporine): lower exposure, risking loss of effect or rejection

CYP2C19 substrates (diazepam, phenytoin): levels can rise

Tricyclics and selective serotonin reuptake inhibitors in CYP2D6 poor metabolizers (clomipramine, fluoxetine): levels may rise

Warfarin: could shift clotting control and bleeding risk

Monoamine oxidase (MAO) inhibitors (phenelzine, selegiline): may add to blood pressure and stimulation

Other stimulants (methylphenidate, dextroamphetamine): additive heart rate, blood pressure and insomnia (theoretical)

Strong CYP3A4 inducers or inhibitors (carbamazepine, ketoconazole): could lower or raise modafinil levels

Proton-pump inhibitors (omeprazole, esomeprazole): raised omeprazole exposure

Decongestants (pseudoephedrine, phenylephrine): additive blood pressure and heart rate (theoretical)

Sedating antihistamines (diphenhydramine, doxylamine): oppose modafinil's alertness (theoretical)

Caffeine: additive jitteriness, anxiety, heart rate and insomnia (theoretical)

Stimulant supplements (synephrine/bitter orange, yohimbine): additive blood pressure, heart rate and anxiety (theoretical)

St John's wort: may lower modafinil levels and further weaken hormonal contraception (theoretical)

CPAP for sleep apnea: using modafinil in place of CPAP leaves the airway obstruction untreated

Alcohol: combined use has not been studied

Sleep restriction and night work: alertness improves but does not normalize; driving after night shifts still carries risk

Risk & Side Effects

High: Headache; insomnia and shortened sleep; nausea, digestive upset and reduced appetite; anxiety and nervousness

Medium: Raised blood pressure, heart rate and cardiovascular symptoms; serious rash, hypersensitivity and blood reactions; overconfidence and masked sleep debt; liver enzyme rises; nose and throat inflammation, back pain, dry mouth and tingling; low mood and dizziness

Low: Birth defects after exposure in pregnancy; psychiatric reactions; misuse and dependence

Speculative: Unknown effects of years of use in healthy brains

Monitoring

Marker	Target	Why
Blood pressure	Below 120/80 mmHg	Safety check: modafinil can raise blood pressure
Resting heart rate	60–100 beats per minute	Safety check: modafinil can raise heart rate
GGT	Men 8–61 U/L, women 5–36 U/L	Safety check: GGT rose in registration trials
ALP	40–129 U/L	Safety check: ALP rose in registration trials
ALT	Not specified in the ER	Liver-injury enzyme, paired with GGT and ALP
Pregnancy test (hCG)	Negative	Safety check: possible birth-defect risk
Sleep duration	No established target; track change from the pre-modafinil baseline	Modafinil can shorten sleep
Epworth Sleepiness Scale	No established target; track change from own baseline	Tracks daytime sleepiness

Cadence: Baseline before the first dose; blood pressure and heart rate at 2 and 4 weeks, then every 3–6 months; liver panel at 3 months, then every 6–12 months during regular use; sleep duration and Epworth score weekly for the first month, then monthly

Qualitative Assessment

Daytime alertness and focus on demanding tasks
Ease of falling asleep and sleep quality
Mood, anxiety and irritability
Appetite and food intake
New skin rash, fever or swelling
Urges to raise the dose or use it more often

Modafinil for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment